A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease

Background: Psychosis is a common and debilitating side effect of long-term dopaminergic treatment of Parkinson disease (PD). While clozapine is an effective treatment, the need for blood monitoring has limited its first-line use.  Objective: Since olanzapine shows similar receptor affinity to cloza...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Michelle J, Hartlein, Johanna M, Eicken, Meredith GA, Racette, Brad A, Black, Kevin J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907164/
https://www.ncbi.nlm.nih.gov/pubmed/24627787
http://dx.doi.org/10.12688/f1000research.2-150.v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907164/
https://www.ncbi.nlm.nih.gov/pubmed/24627787
http://dx.doi.org/10.12688/f1000research.2-150.v1

Ejemplares similares